Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.32 |
| ▸ | CHRNG | P07510 | 2/20 | 0.32 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | CHRND | Q07001 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | CPA1 | P15085 | 1/20 | 0.31 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20806832 | 0.92 | POLB (0.40) | POLBCHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL12533070 | 0.78 | DPP4 (0.45) | POLBMMEACECPA1ACE2 | |
| SCHEMBL13038821 | 0.78 | HSP90AA1 (0.30) | — | |
| SCHEMBL2757930 | 0.77 | POLB (0.43) | POLB | |
| SCHEMBL20207717 | 0.77 | POLB (0.43) | POLB | |
| SCHEMBL14259925 | 0.77 | TDP1 (0.30) | — | |
| SCHEMBL14259922 | 0.75 | — | — | |
| SCHEMBL17407698 | 0.75 | POLB (0.42) | POLB | |
| SCHEMBL23958917 | 0.74 | DPP4 (0.48) | POLBMMEACECPA1ACE2 | |
| SCHEMBL23958961 | 0.74 | DPP4 (0.48) | POLBMMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331738-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230212182-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
| US-11685742-B2 | Anti-tumor compound and preparation method and use thereof | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212182-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | RCC2, REN, VHL | POLB 1590/4885CHRNA1 4443/4885CHRNG 4842/4885 |
| US-20230331738-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | RCC2, REN, VHL | POLB 1590/4885CHRNA1 4443/4885CHRNG 4842/4885 |
| US-11685742-B2 | Anti-tumor compound and preparation method and use thereof | RCC2, REN, VHL | POLB 1590/4885CHRNA1 4443/4885CHRNG 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.